-
2022-501972-25-00
5
2020-04-06
Locally Advanced Cervical Cancer
-
2023-508293-28-00
5
2020-02-20
Dermatomyositis
-
2022-502886-71-00
5
2019-11-20
Previously Untreated Locally Advanced Non-small Cell Lung Cancer (LA N
-
2023-505614-17-00
5
2019-09-20
Participants with advanced or recurrent endometrial carcinoma
-
2023-505167-36-00
5
2019-08-05
Patients who present late on during their acquisition of the HIV-1
(Hu
-
2022-501970-20-01
5
2019-06-07
Cis-eligible Muscle-invasive bladder cancer.
-
2022-501971-24-00
5
2019-05-20
Adjuvant treatment of HCC
-
2023-508832-68-00
9
2019-03-28
Recurrent or stage IVB cervical cancer
-
2023-508127-13-00
4
2019-01-25
Adult patients with refractory or relapsed follicular lymphoma
-
2024-513513-12-00
5
2019-01-06
Cholangiocarcinoma
-
2022-502124-52-00
5
2018-12-18
Advanced epithelial ovarian cancer
-
2024-512158-12-00
5
2018-12-14
Bladder Cancer
Muscle-Invasive Bladder Cancer
-
2023-509061-20-00
9
2018-11-22
Advanced solid tumors
-
2024-511050-44-00
4
2018-05-16
Precursor B-acute lymphoblastic leukemia
-
2024-516783-29-00
6
2018-04-16
Severe allergic and eosinophilic asthma
-
2022-500251-22-00
4
2018-04-12
This study will include all patients having received at least one infu
-
2023-508727-12-00
4
2018-04-12
Relapsed and refractory multiple myeloma (RRMM)
-
2024-516904-40-00
5
2018-03-27
Previously Untreated Diffuse large B-cell lymphoma (DLBCL)
-
2024-518736-37-00
6
2018-01-12
Risk of stroke by Atrial Fibrillation
-
2024-513167-68-00
5
2017-11-29
endometrial cancer
-
2024-513631-25-00
5
2017-08-17
Acute Myeloid Leukemia
-
2024-514698-23-00
5
2017-05-15
Patients with Duchenne Muscular Dystrophy Amenable to Exon 45 or 53 Sk
-
2023-507271-21-00
5
2017-04-11
Follicular Lymphoma
-
2024-511967-26-00
5
2016-11-21
AL Amyloidosis (Newly Diagnosed Systemic AL Amyloidosis)